DOCSLIB.ORG

Pulmonary Overlap Syndromes, with a Focus on COPD And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pulmonary Overlap Syndromes, with a Focus on COPD And 1 Pulmonary Overlap 2 3 4 Syndromes, with a Focus 5 6 on COPD and ILD 7 8 Katherine A. Dudley, MD, Atul Malhotra, MD, Q2Q3 Robert L. Owens, MD* Q4Q5 9 10 KEYWORDS 11 Overlap syndrome Sleep Chronic obstructive pulmonary disease Idiopathic pulmonary fibrosis 12 Obstructive sleep apnea 55 13 56 14 57 15 Q7 KEY POINTS 58 16 59 17 Overlap syndrome refers to the coexistence of chronic lung disease and obstructive sleep apnea 60 18 (OSA) in the same patient. To date, overlap syndromes have been poorly studied for a variety of 61 19 reasons. 62 20 Nevertheless, recent data in chronic obstructive pulmonary disease (COPD) and patients with OSA 63 21 overlap highlight the increased morbidity and mortality of overlap syndromes compared with either 64 22 underlying disorder alone. 65 23 The underlying disorders in overlap syndrome (OSA and chronic lung disease) may be of very 66 24 different severity. Thus, there is a great amount of patient heterogeneity; the goals of therapy 67 25 may differ in different patients. 68 26 Unrecognized OSA may contribute to symptoms of sleepiness and fatigue in those patients with 69 27 chronic lung disease. Thus, clinicians should be mindful of the overlap syndromes in these patients. 70 28 71 29 72 30 73 31 Q8 First described in the 1980s by pulmonologist Da- OVS does, as Flenley thought, have worse out- 74 32 Q9 vid Flenley,1 overlap syndromes (OVSs) refer to the comes than either disease in isolation. These find- 75 33 coexistence of chronic lung disease and obstruc- ings have highlighted the urgent need for further 76 34 tive sleep apnea (OSA). Although it could refer to study of both the OVS and all overlaps between 77 35 78 Q10 any of the lung diseases and OSA, the OVS is usu- OSA and chronic lung disease. 36 ally reserved for the coexistence of OSA and 79 37 chronic obstructive pulmonary disease (COPD), 80 38 which Flenley thought to have unique adverse CLINICAL AND RESEARCH CHALLENGES OF 81 39 health consequences distinct from either condition THE OVS Q11 82 40 alone. Given the high prevalence of each disorder 83 41 OVSs are poorly understood for many reasons. 84 alone, OVS is also likely to be common and clini- Using the OVS as a prototype 42 cally relevant. However, although OVS has been 85 43 described in the literature for nearly 30 years, the 1. The diagnosis of OVS is nebulous, as both OSA 86 44 lack of standard diagnostic criteria for the syn- and COPD are heterogeneous disorders. 45 drome has limited rigorous discussion of diag- COPD and OSA both have wide ranges of 46 nosis, prevalence, pathophysiology, treatment, severity, in terms of both objective measure- 47 and outcomes. These challenges are explored in ments of disease (eg, forced expiratory volume 48 more detail later and throughout this review. in 1 second [FEV1], and apnea-hypopnea index 49 Importantly, several recent studies suggest that [AHI]) and patient-reported symptoms (eg, 50 51 52 Q6 221 Longwood Avenue, BLI 035Q, Boston, MA 02115, USA 53 * Corresponding author. 54 E-mail address: [email protected] Sleep Med Clin - (2014) -–- http://dx.doi.org/10.1016/j.jsmc.2014.05.008 1556-407X/14/$ – see front matter Ó 2014 Published by Elsevier Inc. sleep.theclinics.com CSLP518_proof ■ 10 June 2014 ■ 8:04 pm 2 Dudley et al 87 dyspnea and daytime tiredness). OVS is eliminate apneic events. For a patient with evi- 144 88 defined by the presence of both conditions dence of hypoventilation, the goal may be to 145 89 regardless of the relative burden of one or the improve nocturnal gas exchange and hypercar- 146 90 other. Therefore, patients with OVS may repre- bia. Maybe the best approach would be inten- 147 91 sent a very heterogeneous population, falling sive modification of cardiovascular risk factors 148 92 into one of many potential categories: mild (eg, blood pressure, cholesterol modification). 149 93 COPD with mild OSA, mild COPD with severe These uncertainties contribute to the confusion 150 94 OSA, severe COPD with mild OSA, severe as to the ideal therapy to use. 151 95 COPD with severe OSA, and so forth. Prog- 5. The optimal treatment of OVS is unknown. Few 152 96 nosis and treatment, therefore, could be large clinical trials have been undertaken, and 153 97 considerably different depending on the rela- no large studies have compared long-term out- 154 98 tive impact of each condition. Although it is a comes between randomized therapies. 155 99 minor point, there is not a single International Although continuous positive airway pressure 156 100 Classification of Diseases, Ninth Revision code (CPAP) is the most commonly applied therapy, 157 101 for OVS, which impedes even epidemiologic some groups have used bilevel positive airway 158 102 research. pressure, which provides a higher pressure 159 103 2. The diagnosis of OSA in the setting of hypox- during inspiration than during expiration. Bilevel 160 104 emic lung disease is uncertain. The definition may have benefits over CPAP for some pa- 161 105 of OSA includes hypopneas and reductions in tients, particularly among patients with severe 162 106 airflow with associated desaturation, which is COPD whereby it may aid with nocturnal venti- 163 107 more likely to occur in those with chronic lung lation and resting of respiratory muscles. 164 108 disease. The AHI, used to grade OSA severity, Finally, the role of oxygen therapy, another 165 109 does not differentiate between apneas and hy- treatment used clinically, has not been fully 166 110 popneas. Thus, a patient with severe COPD explored in this population. The role of medical 167 111 might have the same AHI consistent with se- therapy aimed at limiting cardiovascular events 168 112 vere OSA (based on a large number of hypo- has also not been explored. 169 113 pneas) as another patient with a very 6. An additional under-recognized consideration 170 114 collapsible upper airway without lung disease is that sleep is poor in chronic lung diseases, in- 171 115 (who predominantly has apneas). In addition, dependent of upper airway collapse. Many 172 116 a 10-minute prolonged desaturation caused studies have highlighted the high prevalence 173 117 by hypoventilation may be scored as a single of sleep complaints among patients with 174 118 hypopnea because the event duration has min- chronic lung diseases. There are many reasons 175 119 imal effect on the definitions used. More behind this finding, ranging from cough inter- 176 120 rigorous definitions of OSA might be useful, fering with sleep, increased anxiety and 177 121 such as the apnea index or scoring based on insomnia, side effects of medications (eg, 178 122 airflow alone and arousals independent of oxy- chronic glucocorticoids, beta agonists), and 179 123 gen desaturation. frequent arousals. Although treatment of OVS 180 124 3. The interactions of COPD and OSA are not un- with CPAP may improve upper airway patency, 181 125 derstood. Thus, it is unknown at a pathophysi- CPAP will not address many of the nonrespira- 182 126 ologic level whether each disorder might tory problems that plague sleep in this popula- 183 127 predispose to the other disease. As discussed tion. Thus, CPAP adherence may be 184 128 earlier, the baseline hypoxemia of COPD likely challenged in ways that are unique compared 185 129 predisposes to a diagnosis of OSA. But other with those without chronic lung disease. 186 130 links are possible; for example, the changes in 187 131 lung volumes that occur with COPD might These points are illustrated as the authors 188 132 impact upper airway collapsibility. How COPD discuss what is known about OVS (and OSA and 189 133 and OSA interact to cause the increased idiopathic pulmonary fibrosis [IPF]), perhaps the 190 134 morbidity and mortality attributable to OVS is most common of the interstitial lung diseases (ILDs). 191 135 not known. Is it simply from more prolonged 192 136 hypoxemia or hypercapnia than either disorder COPD AND OSA 193 137 alone? Or are poor outcomes caused by the in- 194 Throughout this section, OVS refers exclusively to 138 direct effects of the disorders, such as cardio- 195 those with COPD and OSA. 139 vascular disease? 196 140 4. Thus, the goals of therapy in OVS are poorly 197 COPD 141 defined. For a patient with severe OSA with 198 142 many apneas, the goal of therapy may be to COPD is a progressive lung disease characterized 199 143 200 support patency of the upper airway and by irreversible airway obstruction (FEV1/forced CSLP518_proof ■ 10 June 2014 ■ 8:04 pm Q1 Pulmonary Overlap Syndromes 3 201 vital capacity [FVC]<70%). This disease can COPD may play a role in cardiovascular disease 258 202 involve the small airways, pulmonary parenchyma, include increased oxidative stress, inflammation, 259 203 or both. COPD results from an inflammatory and increased platelet activation. 260 204 response that can result in chronic sputum pro- Of particular interest in the current discussion, 261 205 duction (chronic bronchitis) as well as the destruc- COPD is a heterogeneous disorder, with variable 262 206 tion of alveolar walls distal to the terminal amounts of airway and parenchymal disease. 263 207 bronchioles, leading to enlargement of the air- Most patients have a predominance of one pheno- 264 208 spaces (emphysema). Although tobacco use is type, though there is usually some overlap. In the 265 209 strongly associated with the development of past, patients with chronic bronchitis were 266 210 COPD, it is not the only risk factor. In developing described as blue bloaters, referring to hypox- 267 211 countries, exposure to indoor air pollution plays a emia, polycythemia, and cor pulmonale that often 268 212 critical role, in particular as a result of fuels burned accompanies patients with this form of COPD.
Load more

Recommended publications
  • Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality
    Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality Please note, this report is designed for double-sided printing American Lung Association Epidemiology and Statistics Unit Research and Health Education Division March 2013 Page intentionally left blank Table of Contents COPD Mortality, 1999-2009 COPD Prevalence, 1999-2011 COPD Hospital Discharges, 1999-2010 Glossary and References List of Tables Table 1: COPD – Number of Deaths by Ethnic Origin and Sex, 1999-2009 Figure 1: COPD – Number of Deaths by Sex, 1999-2009 Figure 2: COPD – Age-Adjusted Death Rates by Ethnic Origin and Sex, 2009 Table 2: COPD – Age-Adjusted Death Rate per 100,000 Population by Ethnic Origin and Sex, 1999- 2009 Figure 3: COPD – Deaths and Age-Adjusted Death Rate by Sex, 2009 Figure 4: COPD – Diagnosed Cases and Evidence of Impaired Lung Function Figure 5: Chronic Bronchitis – Prevalence Rates per 1,000, 2011 Table 3: Chronic Bronchitis – Number of Conditions and Prevalence Rate per 1,000 Population by Ethnic Origin, Sex and Age, 1999-2011 Figure 6: Emphysema – Prevalence Rates per 1,000, 2011 Table 4: Emphysema – Number of Conditions and Prevalence Rate per 1,000 Population by Ethnic Origin, Sex and Age, 1997-2011 Table 5: COPD – Adult Prevalence by Sex and State, 2011 Figure 8: COPD – Age-Adjusted Prevalence in Adults by State, 2011 Table 6: Characteristics Among Those Reporting a Diagnosis of COPD by State (%), 2011 Figure 9: COPD – First-Listed Hospital Discharge Rates per 10,000, 2010 Table 7: COPD – Number of First-Listed Hospital Discharges and Rate per 10,000 Population by Race, Sex and Age, 1999-2010 Figure 9: National Projected Annual Cost of COPD, 2010 Introduction Chronic obstructive pulmonary disease (COPD) is a term which refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing.
    [Show full text]
  • Chronic Obstructive Lung Disease &​Bronchiectasis
    PLEASE CHECK Editing file BEFORE! ​ ​ ​ ​ Chronic Obstructive lung Disease & Bronchiectasis ​ ★ Objectives: ​ 1. Definition of the two conditions 2. Clinical and radiological diagnosis 3. Differential diagnosis 4. General outline of management 5. Create a link to 341 clinical teaching ★ Resources Used in This lecture: Davidson, Guyton and Becker step 1 lecture notes ​ Done by: Mohammad Alkharraz Contact us at: [email protected] Chronic Obstructive Pulmonary Diseases (COPD) COPD contains two diseases which are chronic bronchitis and emphysema ​ ​ ​ ■ COPD is classified under obstructive pulmonary diseases along with other ​(no kidding!)​ diseases such as asthma and bronchiectasis ■ Chronic bronchitis and emphysema are grouped together under COPD because they are both mainly caused by smoking and they usually present together. ​ ■ Brainless pathology textbooks (Robbins) try to confuse us students with “Pink Puffers” and “Blue Bloaters”. Forget about that as it is not clinically relevant1. Let us quickly point out some points (pathology) that are relevant to each disease (chronic bronchitis and emphysema) and then we will discuss the clinical presentation, management, etc. of COPD Chronic bronchitis It is mainly a clinical diagnosis patients cough up lots of sputum for a long period of time ​ ​ “3 months per year for at least 2 consecutive years2” ● Pathogenesis: Cigarette smoke causes hyperplasia of mucus glands which increase the ​ secretion of mucus → mucus plugs cause obstruction of bronchioles→ COPD Emphysema It is mainly a pathological diagnosis. ​ ​ ● Pathogenesis: 1. Pollutants (smoking)→ increased inflammatory mediators in the lung that destroy the lung parenchyma (trypsin and elastase) 2. We have defense mechanisms to fight these inflammatory mediators (alpha1 antitrypsin) ○ However, the amount of inflammatory mediators exceeds our ability to counteract them 3.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis As a Cause of Bronchial Asthma in Children
    Egypt J Pediatr Allergy Immunol 2012;10(2):95-100. Original article Allergic bronchopulmonary aspergillosis as a cause of bronchial asthma in children Background: Allergic bronchopulmonary aspergillosis (ABPA) occurs in Dina Shokry, patients with asthma and cystic fibrosis. When aspergillus fumigatus spores Ashgan A. are inhaled they grow in bronchial mucous as hyphae. It occurs in non Alghobashy, immunocompromised patients and belongs to the hypersensitivity disorders Heba H. Gawish*, induced by Aspergillus. Objective: To diagnose cases of allergic bronchopulmonary aspergillosis among asthmatic children and define the Manal M. El-Gerby* association between the clinical and laboratory findings of aspergillus fumigatus (AF) and bronchial asthma. Methods: Eighty asthmatic children were recruited in this study and divided into 50 atopic and 30 non-atopic Departments of children. The following were done: skin prick test for aspergillus fumigatus Pediatrics and and other allergens, measurement of serum total IgE, specific serum Clinical Pathology*, aspergillus fumigatus antibody titer IgG and IgE (AF specific IgG and IgE) Faculty of Medicine, and absolute eosinophilic count. Results: ABPA occurred only in atopic Zagazig University, asthmatics, it was more prevalent with decreased forced expiratory volume Egypt. at the first second (FEV1). Prolonged duration of asthma and steroid dependency were associated with ABPA. AF specific IgE and IgG were higher in the atopic group, they were higher in Aspergillus fumigatus skin Correspondence: prick test positive children than negative ones .Wheal diameter of skin prick Dina Shokry, test had a significant relation to the level of AF IgE titer. Skin prick test Department of positive cases for aspergillus fumigatus was observed in 32% of atopic Pediatrics, Faculty of asthmatic children.
    [Show full text]
  • Cryptogenic Organizing Pneumonia—Results of Treatment with Clarithromycin Versus Corticosteroids—Observational Study
    RESEARCH ARTICLE Cryptogenic organizing pneumoniaÐResults of treatment with clarithromycin versus corticosteroidsÐObservational study Elżbieta Radzikowska1*, Elżbieta Wiatr1☯, Renata Langfort2³, Iwona Bestry3³, Agnieszka Skoczylas4, Ewa Szczepulska-Wo jcik2³, Dariusz Gawryluk1☯, Piotr Rudziński5³, Joanna Chorostowska-Wynimko6³, Kazimierz Roszkowski-Śliż1³ 1 III Department of Lung Disease National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 2 Pathology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 3 Radiology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, a1111111111 Poland, 4 Geriatrics Department National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, a1111111111 Poland, 5 Thoracic Surgery Department National Tuberculosis and Lung Diseases Research Institute, a1111111111 Warsaw, Poland, 6 Laboratory of Molecular Diagnostics and Immunology National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland a1111111111 a1111111111 ☯ These authors contributed equally to this work. ³ These authors also contributed equally to this work. * [email protected] OPEN ACCESS Abstract Citation: Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-WoÂjcik E, et al. (2017) Cryptogenic organizing pneumoniaÐ Background Results of treatment with clarithromycin versus Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown ori- corticosteroidsÐObservational study. PLoS ONE 12(9): e0184739.
    [Show full text]
  • Chronic Obstructive Pulmonary Disease (Copd) in the Americas
    CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE AMERICAS KEY STATISTICS FOR THE AMERICAS An estimated 13.2 million people live with COPD (1). COPD caused over 235,000 deaths in 2010, ranking as the sixth leading cause of death (2). 7 in 10 COPD deaths are attributable to tobacco (3). In 2012, COPD was responsible for the loss of 8.3 million disability-adjusted life years (DALYs) (3). KEY MESSAGES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A LEADING CAUSE OF MORBIDITY AND MORTALITY IN THE 1 AMERICAS, REPRESENTING AN IMPORTANT PUBLIC HEALTH CHALLENGE THAT IS BOTH PREVENTABLE AND TREATABLE. COPD is an incurable disease, characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lungs. Common symptoms include breathlessness, abnormal sputum and a chronic cough. Exacerbations and comorbidities – such as cardiovascular diseases, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression and lung cancer – contribute to the overall severity of individual patients (4,5). In 2010, COPD accounted for over 235,000 deaths in the Americas, ranking as the sixth leading cause of mortality regionally. About 23% of these deaths occurred prematurely, in people aged 30-69 years (2). An estimated 13.2 million people live with COPD in the region (1). Many people suffer from this disease for years, experiencing disa- bility and major adverse effects on their quality of life (5,6). In 2012, COPD was responsible for the loss of 8.3 million DALYs, representing the seventh leading cause of disability-adjusted life years lost (DALYs) in the Americas, with one DALY representing the loss of the equivalent of one year of full health (3,6).
    [Show full text]
  • Interstitial Lung Disease—Raising the Index of Suspicion in Primary Care
    www.nature.com/npjpcrm All rights reserved 2055-1010/14 PERSPECTIVE OPEN Interstitial lung disease: raising the index of suspicion in primary care Joseph D Zibrak1 and David Price2 Interstitial lung disease (ILD) describes a group of diseases that cause progressive scarring of the lung tissue through inflammation and fibrosis. The most common form of ILD is idiopathic pulmonary fibrosis, which has a poor prognosis. ILD is rare and mainly a disease of the middle-aged and elderly. The symptoms of ILD—chronic dyspnoea and cough—are easily confused with the symptoms of more common diseases, particularly chronic obstructive pulmonary disease and heart failure. ILD is infrequently seen in primary care and a precise diagnosis of these disorders can be challenging for physicians who rarely encounter them. Confirming a diagnosis of ILD requires specialist expertise and review of a high-resolution computed tomography scan (HRCT). Primary care physicians (PCPs) play a key role in facilitating the diagnosis of ILD by referring patients with concerning symptoms to a pulmonologist and, in some cases, by ordering HRCTs. In our article, we highlight the importance of prompt diagnosis of ILD and describe the circumstances in which a PCP’s suspicion for ILD should be raised in a patient presenting with chronic dyspnoea on exertion, once more common causes of dyspnoea have been investigated and excluded. npj Primary Care Respiratory Medicine (2014) 24, 14054; doi:10.1038/npjpcrm.2014.54; published online 11 September 2014 INTRODUCTION emphysema, in which the airways of the lungs become narrowed Interstitial lung disease (ILD) is an umbrella term, synonymous or blocked so the patient cannot exhale completely.
    [Show full text]
  • Radioaerosol Lung Scanning in Chronic Obstructive Pulmonary Disease (COPD) and Related Disorders
    88 XAOIOOIOO Radioaerosol Lung Scanning in Chronic Obstructive Pulmonary Disease (COPD) and Related Disorders Yong Whee Bahk, M.D. and Soo Kyo Chung, M.D. Introduction As a coordinated research project of the International Atomic Energy Agency (IAEA) a multicentre joint study on radioaerosol lung scan using the BARC nebulizer [1] has prospectively been carried out during 1988-1992 with the participation of 10 member countries in Asia [Bangladesh, China, India, Indonesia, Japan, Korea, Pakistan, Philippines, Singapore and Thailand]. The study was designed so that it would primarily cover chronic obstructive pulmonary disease (COPD) and the other related and common pulmonary diseases. The study also included normal controls and asymptomatic smokers. The purposes of this presentation are three fold: firstly, to document the useful- ness of the nebulizer and the validity of user's protocol in imaging COPD and other lung diseases; secondly, to discuss scan features of the individual COPD and other disorders studied and thirdly, to correlate scan alterations with radiographie find- ings. Before proceeding with a systematic analysis of aerosol scan patterns in the disease groups, we documented normal pattern. The next step was the assessment of scan features in those who had been smoking for more than several years but had no symptoms or signs referable to airways. The lung diseases we analyzed included COPD [emphysema, chronic bronchitis, asthma and bronchiectasis], bron- chial obstruction, compensatory overinflation and other common lung diseases such as lobar pneumonia, tuberculosis, interstitial fibrosis, diffuse panbronchiolitis, lung edema and primary and metastatic lung cancers. Lung embolism, inhalation burns and glue-sniffer's lung are seperately discussed by Dr.
    [Show full text]
  • Global Initiative for Chronic Obstructive Lung Disease (2006)
    Global Initiative for Chronic Obstructive Lung Disease GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 2006 Copyright © 2006 MCR VISION, Inc. All Rights Reserved GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2006) © 2006 Global Initative for Chronic Obstructive Lung Disease i Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006) GOLD EXECUTIVE COMMITTEE* Roberto Rodriguez Roisin, MD Hospital Clinic A. Sonia Buist, MD, Chair Barcelona, Spain Oregon Health & Science University Portland, Oregon, USA Thys van der Molen, MD University of Groningen Antonio Anzueto, MD Groningen, The Netherlands (Representing the American Thoracic Society) University of Texas Health Science Center Chris van Weel, MD San Antonio, Texas, USA (Representing the World Organization of Family Doctors (WONCA)) Peter Calverley, MD University of Nijmegen University Hospital Aintree Nijmegen, The Netherlands Liverpool, UK GOLD SCIENCE COMMITTEE* Teresita S. deGuia, MD Philippine Heart Center Klaus F. Rabe, MD, PhD, Chair Quezon City, Philippines Leiden University Medical Center Leiden, The Netherlands Yoshinosuke Fukuchi, MD (Representing the Asian Pacific Society for Respirology) A. G. Agusti, MD (Effective June 2006) Tokyo, Japan Hospital Universitari Son Dureta Palma de Mallorca, Spain Christine Jenkins, MD Woolcock Institute of Medical Research Antonio Anzueto, MD Sydney, NSW, Australia University of Texas Health Science Center San Antonio, Texas, USA Nikolai Khaltaev, MD (Representing the World Health Organization) Peter J. Barnes, MD Geneva, Switzerland National Heart and Lung Institute London, UK James Kiley, PhD (Representing the National Heart, Lung, and Blood Institute, A.
    [Show full text]
  • 2020 GOLD Pocket Guide
    DISTRIBUTE OR COPY NOT DO - MATERIAL COPYRIGHT POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals 2020 REPORT GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals 2020 EDITION DISTRIBUTE OR COPY NOT DO - MATERIAL COPYRIGHT © 2020 Global Initiative for Chronic Obstructive Lung Disease, Inc. i GOLD BOARD OF DIRECTORS GOLD SCIENCE COMMITTEE* (2019) (2019) Alvar Agusti, MD, Chair Claus Vogelmeier, MD, Chair Maria Montes de Oca, MD Respiratory Institute, University of Marburg Hospital Universitario de Caracas Hospital Clinic, IDIBAPS Marburg, Germany Universidad Central de Venezuela Univ. Barcelona and Ciberes Caracas, Venezuela Barcelona, Spain Alvar Agusti, MD Respiratory Institute, Hospital Alberto Papi, MD Richard Beasley, MD Clinic, IDIBAPS University of Ferrara Medical Research Institute of NZ, Univ. Barcelona and Ciberes Ferrara, Italy Wellington, New Zealand Barcelona, Spain Ian Pavord, MA DM Bartolome R. Celli, MD Antonio Anzueto, MD Respiratory Medicine Unit and Oxford Brigham and Women’s Hospital South Texas Veterans Health Care System, Respiratory NIHR Biomedical Research Boston, Massachusetts, USA University of Texas, Health Centre San Antonio, Texas, USA Nuffield Department of Medicine Rongchang Chen, MD University of Oxford Guangzhou Institute of Respiratory Peter Barnes, DM, FRS Oxford, UK Disease National Heart & Lung Institute, Guangzhou, PRC Imperial College Nicolas Roche, MD London,
    [Show full text]
  • Copd: Myths & Misconceptions
    COPD: MYTHS & MISCONCEPTIONS Chronic obstructive pulmonary disease or COPD is a chronic disease of the lungs. Although COPD is a common lung disease there are still misconceptions that surround it. Read on to find out some of the more common COPD myths and the facts that dispel them. 1 MYTH: SHORTNESS OF BREATH IS THE ONLY SYMPTOM OF COPD FACT: Breathlessness is one of the symptoms of COPD but other common signs to look out for include tiredness, a persistent cough which produces phlegm, chest infections and wheezing.1 MYTH: COPD ONLY HAPPENS TO OLDER PEOPLE 2 FACT: COPD can begin in your 40s, or even earlier, although many people are often not diagnosed until their 50s and 60s.2 3 MYTH: COPD IS THE SAME AS ASTHMA FACT: Although symptoms appear similar, asthma and COPD are not the same.3 It is important to get the correct diagnosis from your doctor. MYTH: EXERCISE WILL MAKE COPD WORSE 4 FACT: Exercise has been shown to be safe and beneficial for most people with COPD.4,5 Speak to your doctor or nurse about gentle exercises that are suitable for you. 5 MYTH: SMOKING IS THE ONLY CAUSE OF COPD FACT: Although smoking is a leading cause, exposure to fumes, chemicals, dust or harmful pollutants can also result in COPD developing.6,7 MYTH: A HEALTHY DIET WILL NOT HELP WITH COPD 6 FACT: Maintaining a well-balanced diet, including eating fresh fruit and vegetables, can help you to increase your energy levels and improve your health.8,9,10 7 MYTH: WEIGHT DOES NOT AFFECT COPD FACT: Extra weight can make you more breathless and your symptoms worse.
    [Show full text]
  • Surgical Pathology of Non-Neoplastic Lung Disease Thomas V
    SHORT COURSE Surgical Pathology of Non-Neoplastic Lung Disease Thomas V. Colby, M.D. Department of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona At inception, this course included some neoplastic Case 1: Acute Exacerbation of Idiopathic lesions, but each year, the case mix was changed in Pulmonary Fibrosis response to the comments (and criticism) of the A 51-year-old man had experienced 3 to 4 years attendees. As cases were added and deleted, in the of progressive dyspnea and interstitial infiltrates as end only examples of non-neoplastic lung disease observed on chest radiographs. One week before were discussed. Of the 19 cases used during the death, there was acute worsening of his dyspnea, course of 5 years, the following 8 were selected for with some associated chills and a sore throat. At this presentation. admission, he was hypoxemic, tachypneic, and afe- brile. The clinical impression was an acute (possibly CASES 1, 2, AND 3: IDIOPATHIC INTERSTITIAL infectious) process superimposed on idiopathic PNEUMONIAS AND RELATED LESIONS pulmonary fibrosis (IPF). An open-lung biopsy was performed. The patient died 1 week later. Cultures To the clinician, there are well over 100 causes of and special stains were negative. interstitial pneumonia, but among these, there is a select subgroup that has been called the idiopathic Histologic findings interstitial pneumonias. This group has evolved The open biopsy shows subpleural scarring and from Liebow and Carrington’s (1) classic classifica- microscopic honeycombing, with associated tion of chronic interstitial pneumonias: smooth muscle metaplasia and fibroblastic foci Usual interstitial pneumonia (UIP) (Figs. 1 and 2).
    [Show full text]
  • Aspergillus Fumigatus During Stable State and Exacerbations of Chronic
    ERJ Express. Published on April 18, 2013 as doi: 10.1183/09031936.00162912 Aspergillus fumigatus during stable state and exacerbations of chronic obstructive pulmonary disease Mona Bafadhel1 PhD, [email protected] Susan Mckenna1 RGN, [email protected] Joshua Agbetile1 MBChB, [email protected] Abbie Fairs1 BSc,[email protected] Dhananjay Desai1 MBBS, [email protected] Vijay Mistry1 BSc, [email protected] Joseph P Morley1 BSc, [email protected] Mitesh Pancholi1 BSc, [email protected] Ian D Pavord1 MD, [email protected] Andrew J Wardlaw1 PhD, [email protected] *Catherine H Pashley1 PhD, [email protected] *Christopher E Brightling1 PhD, [email protected] * Joint senior authors Running title: Aspergillus fumigatus in COPD Manuscript word count: 2500 Keywords Aspergillus; Atopy; COPD; exacerbation; FEV1; fungi; neutrophil; 1 Copyright 2013 by the European Respiratory Society. 1Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, Department of Infection, Immunity and Inflammation, The University of Leicester, Leicester. United Kingdom Address for correspondence: Dr Mona Bafadhel, Institute for Lung Health, Glenfield Hospital, Leicester, LE3 9QP, UK; Tel: +44 116 256 3789; Email: [email protected] Source of funding The study was funded by the Medical Research Council (UK), a senior Wellcome Fellowship (CEB) and the Midlands Asthma Allergy Research Association (MAARA); and the research was performed in laboratories part funded by the European Regional Development Fund (ERDF 05567). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
    [Show full text]